About Zealand Marketed Products R&D Investor Media Careers Contact Investor relations Corporate presentation Stock information Shareholder portal Financial calendar Financial reports Events Annual General Meeting Conference calls SEC filings Analyst Coverage Investor relations Zealand maintains an active approach to IR in order to provide transparency into our business and our activities. An open and transparent communication is the best way to maintain the confidence of our shareholders, and we achieve this through company announcements, investor meetings, company presentations, our company website and social media. In line with the disclosure requirements for companies listed on NASDAQ Copenhagen as well as having American Depositary Shares representing Zealand shares Trading on Nasdaq Global Select Market in New York, Zealand issues announcements to inform of relevant news relating the company and its business activities. Further, we issue investor news on a frequent basis and hold conference calls in order to reach investors effectively. We also attend and present at investor conferences and one-to-one meetings in both the Europe and the U.S., we also travel to the main financial cities frequently to meet with investors. We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner. We encourage investors, analysts and other external stakeholders to contact us with any questions or other inquiries relating to Zealand. Please find our IR Policy here. Information Alerts Register here to receive news releases directly. For all shareholders, please register your email address via the Shareholder portal. Investor Contact Matt Dallas Zealand Pharma mdallas@zealandpharma.com David Rosen Argot Partners media@zealandpharma.com Questions for the Investor Relations department can also be emailed to investors@zealandpharma.com Zealand Pharma A/S Sydmarken 11 2860 Søborg Denmark Tel +45 88 77 36 00 info@zealandpharma.com Legal disclaimer Privacy policy This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. Read our privacy policy for more information. Accept

About Zealand Marketed Products R&D Investor Media Careers Contact Our focus Product pipeline Glepaglutide for SBS Dasiglucagon for BHAP systems Dasiglucagon for CHI BI 456906 GLP-1/GLU Dual Agonist Amylin analogue, ZP8396 Inlicensing What are peptides? Peptide Platform Video Zealand Pharma A/S Sydmarken 11 2860 Søborg Denmark Tel +45 88 77 36 00 info@zealandpharma.com Legal disclaimer Privacy policy This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. Read our privacy policy for more information. Accept